CLIC1 Inhibitor Program

About ClicBio

ClicBio is a preclinical-stage biotech founded in 2021, pioneering a new class of oral, small-molecule CLIC1 inhibitors for obesity and metabolic disease. The company's science is based on inhibiting CLIC1, a protein that translocates to the membrane of hunger-promoting AgRP neurons during fasting; blocking this process reduces food intake, increases energy expenditure, and may offer a superior side-effect profile compared to GLP-1 therapies. With a seasoned leadership team of biotech veterans and a clear path toward clinical development, ClicBio is positioning itself to compete in the massive obesity market, either as a monotherapy or in combination with existing treatments. The company is privately held and headquartered in Cambridge, Massachusetts.

Therapeutic Areas

Other Obesity / Metabolic Disease Drugs